Patents by Inventor Hung-Teh Kao

Hung-Teh Kao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8709981
    Abstract: The present invention concerns novel isolated fluorescent proteins, variants thereof, and polynucleotides encoding the same. Methods for making and using the polypeptides and polynucleotides are also provided. For example, methods to detect protein-protein interactions, to develop novel fluorescent reagents, to monitor cellular events, as well as cell-based methods for screening for kinase or phosphatase inhibitors, are set forth. Kits to carry out the methods of the invention are also taught.
    Type: Grant
    Filed: September 16, 2010
    Date of Patent: April 29, 2014
    Inventors: David Gruber, Hung-Teh Kao, Vincent Pieribone
  • Publication number: 20120252698
    Abstract: The present invention concerns novel isolated fluorescent proteins, variants thereof, and polynucleotides encoding the same. Methods for making and using the polypeptides and polynucleotides are also provided. For example, methods to detect protein-protein interactions, to develop novel fluorescent reagents, to monitor cellular events, as well as cell-based methods for screening for kinase or phosphatase inhibitors, are set forth. Kits to carry out the methods of the invention are also taught.
    Type: Application
    Filed: September 16, 2010
    Publication date: October 4, 2012
    Inventors: David Gruber, Hung-Teh Kao, Vincent Pieribone
  • Publication number: 20030082645
    Abstract: A new synapsin protein, designated synapsin III, its amino acid sequence, and its human gene have been isolated and characterized. Furthermore, isoforms of synapsin III, e.g., synapsin IIIa, IIIb and IIIc, and have isolated and characterized, and cDNA encoding these isoforms has also been isolated and characterized. The synapsin III gene is located on human chromosome 22, in the vicinity of a region previously identified as a susceptibility locus for schizophrenia. The information and experimental tools provided by this discovery can be used to generate new therapeutic agents or diagnostic assays for this new protein, its associated mRNA or its associated genomic DNA. Due to its role in neurotransmission and synaptogenesis, isoforms of synapsin III are associated with the symptoms of psychiatric diseases, especially schizophrenia.
    Type: Application
    Filed: April 15, 2002
    Publication date: May 1, 2003
    Inventors: Paul Greengard, Barbara Porton, Hung-Teh Kao
  • Patent number: 6429010
    Abstract: A new synapsin protein, designated synapsin III, its amino acid sequence, and its human gene have been isolated and characterized. Furthermore, isoforms of synapsin III, e.g., synapsin IIIa, IIIb and IIIc, and have isolated and characterized, and cDNA encoding these isoforms has also been isolated and characterized. The synapsin III gene is located on human chromosome 22, in the vicinity of a region previously identified as a susceptibility locus for schizophrenia. The information and experimental tools provided by this discovery can be used to generate new therapeutic agents or diagnostic assays for this new protein, its associated mRNA or its associated genomic DNA. Due to its role in neurotransmission and synaptogenesis, isoforms of synapsin III are associated with the symptoms of psychiatric diseases, especially schizophrenia.
    Type: Grant
    Filed: August 5, 1998
    Date of Patent: August 6, 2002
    Assignee: The Rockefeller University
    Inventors: Paul Greengard, Barbara Porton, Hung-Teh Kao
  • Publication number: 20020098548
    Abstract: The present invention provides an isolated nucleic acid molecule encoding an 5-HT2 receptor, and an isolated protein which is a human 5-HT2 receptor.
    Type: Application
    Filed: August 14, 2001
    Publication date: July 25, 2002
    Applicant: Synaptic Pharmaceutical Corporation
    Inventors: Hung-Teh Kao, Paul R. Hartig, Theresa Branchek
  • Publication number: 20020064811
    Abstract: A new synapsin protein, designated synapsin III, its amino acid sequence, and its human gene have been isolated and characterized. Furthermore, isoforms of synapsin III, e.g., synapsin IIIa, IIIb and IIIc, and have isolated and characterized, and cDNA encoding these isoforms has also been isolated and characterized. The synapsin III gene is located on human chromosome 22, in the vicinity of a region previously identified as a susceptibility locus for schizophrenia. The information and experimental tools provided by this discovery can be used to generate new therapeutic agents or diagnostic assays for this new protein, its associated mRNA or its associated genomic DNA. Due to its role in neurotransmission and synaptogenesis, isoforms of synapsin III are associated with the symptoms of psychiatric diseases, especially schizophrenia.
    Type: Application
    Filed: August 5, 1998
    Publication date: May 30, 2002
    Inventors: PAUL GREENGARD, BARBARA PORTON, HUNG-TEH KAO
  • Patent number: 6383762
    Abstract: The present invention provides a method of obtaining a composition which comprises determining whether a chemical compound binds to a human 5-HT2 receptor expressed on the surface of a mammalian cell transfected with a vector adapted for expressing the receptor in the cell, and if the compound binds to the receptor, admixing the compound with a carrier. The present invention further provides a method of obtaining a composition which comprises determining whether a chemical compound binds to and activates or binds to and inhibits activation of a human 5-HT2 receptor expressed on the surface of a mammalian cell, wherein the human 5-HT2 receptor is expressed on the surface of a mammalian cell transfected with a vector adapted for expressing the receptor in the cell, and if the compound binds to and activates or binds to and inhibits activation of the receptor, admixing the compound with a carrier.
    Type: Grant
    Filed: September 2, 1998
    Date of Patent: May 7, 2002
    Assignee: Synaptic Pharmaceutical Corporation
    Inventors: Hung-Teh Kao, Paul R. Hartig, Theresa Branchek
  • Patent number: 6040168
    Abstract: A new synapsin protein, designated synapsin III, its amino acid sequence, and its human gene have been isolated and characterized. The synapsin III gene is located on human chromosome 22, in the vicinity of a region previously identified as a susceptibility locus for schizophrenia. The information and experimental tools provided by this discovery can be used to generate new therapeutic agents or diagnostic assays for this new protein, its associated mRNA or its associated genomic DNA. Due to its role in neurotransmission and synaptogenesis, this synapsin III is associated with the symptoms of psychiatric diseases, especially schizophrenia.
    Type: Grant
    Filed: August 6, 1997
    Date of Patent: March 21, 2000
    Assignee: The Rockefeller University
    Inventors: Paul Greengard, Barbara Porton, Hung-Teh Kao
  • Patent number: 5885785
    Abstract: The present invention provides an isolated nucleic acid molecule encoding a 5-HT.sub.2 receptor, and an isolated protein which is a human 5-HT.sub.2 receptor. The invention also provides vectors comprising DNA molecules encoding a human 5-HT.sub.2 receptor, and vectors adapted for expression of the 5-HT.sub.2 receptor in bacterial, yeast, or mammalian cells. In addition, the invention provides a DNA probe useful for detecting nucleic acid encoding the 5-HT.sub.2 receptor, a method for determining whether a ligand which is not known to be capable of binding to the 5-HT.sub.2 receptor can bind to the 5-HT.sub.2 receptor, a method for detecting the presence of 5-HT.sub.2 receptor on the surface of a cell, and a method of screening drugs to identify drugs which specifically interact with, and bind to, the 5-HT.sub.2 receptor. The invention herein also concerns an antibody directed to the human 5-HT.sub.2 receptor, such as a monoclonal antibody directed to an epitope of the 5-HT.sub.
    Type: Grant
    Filed: March 8, 1996
    Date of Patent: March 23, 1999
    Assignee: Synaptic Pharmaceutical Corporation
    Inventors: Hung-Teh Kao, Paul R. Hartig, Theresa Branchek
  • Patent number: 5661024
    Abstract: The present invention provides an isolated nucleic acid molecule encoding an 5-HT.sub.2 receptor, and an isolated protein which is a human 5-HT.sub.2 receptor.The invention also provides vectors comprising DNA molecules encoding a human 5-HT.sub.2 receptor, and vectors adapted for expression of the 5-HT.sub.2 receptor in bacterial, yeast, or mammalian cells.In addition, the invention provides a DNA probe useful for detecting nucleic acid encoding the 5-HT.sub.2 receptor, a method for determining whether a ligand which is not known to be capable of binding to the 5-HT.sub.2 receptor can bind to the 5-HT.sub.2 receptor, a method for detecting the presence of 5-HT.sub.2 receptor on the surface of a cell, and a method of screening drugs to identify drugs which specifically interact with, and bind to, the 5-HT.sub.2 receptor.The invention herein also concerns an antibody directed to the human 5-HT.sub.2 receptor, such as a monoclonal antibody directed to an epitope of the 5-HT.sub.
    Type: Grant
    Filed: November 30, 1994
    Date of Patent: August 26, 1997
    Assignee: Synaptic Pharmaceutical Corporation
    Inventors: Hung-Teh Kao, Paul R. Hartig, Theresa Branchek